LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.66 3.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.63

Max

0.73

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1M

-1.2M

Pardavimai

141K

21M

Pelno marža

-5.978

Darbuotojai

330

EBITDA

42K

197K

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+203.03% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

321K

26M

Ankstesnė atidarymo kaina

-2.47

Ankstesnė uždarymo kaina

0.66

Naujienos nuotaikos

By Acuity

50%

50%

185 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Harvard Bioscience Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-17 18:59; UTC

Pagrindinės rinkos jėgos

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025-11-17 23:40; UTC

Rinkos pokalbiai

Gold Consolidates Amid Mixed Signals -- Market Talk

2025-11-17 23:34; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-11-17 22:58; UTC

Rinkos pokalbiai

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025-11-17 22:46; UTC

Rinkos pokalbiai

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025-11-17 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Rev $2.6B >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q EPS $4.02 >TCOM

2025-11-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Adj EPS 26c >JHX

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025-11-17 21:39; UTC

Uždarbis

James Hardie Industries 2Q Sales $1.29B >JHX

2025-11-17 21:38; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 21:38; UTC

Uždarbis

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q EPS BRL2.47 >XP

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q Rev BRL4.67B >XP

2025-11-17 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-17 20:09; UTC

Rinkos pokalbiai

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025-11-17 19:29; UTC

Rinkos pokalbiai

Gold Slide Continues to Start Week -- Market Talk

2025-11-17 19:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 18:20; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025-11-17 16:45; UTC

Įsigijimai, susijungimai, perėmimai

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025-11-17 16:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 16:15; UTC

Uždarbis

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025-11-17 15:40; UTC

Įsigijimai, susijungimai, perėmimai

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025-11-17 15:22; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025-11-17 15:19; UTC

Rinkos pokalbiai

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harvard Bioscience Inc Prognozė

Kainos tikslas

By TipRanks

203.03% į viršų

12 mėnesių prognozė

Vidutinis 2 USD  203.03%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harvard Bioscience Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.3 / 0.3401Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

185 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat